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Forced inspiratory measures have been described to reflect the reduction in dyspnoea upon
bronchodilation in severe COPD. Based on this we evaluated the applicability and usefulness
of a portable device for the assessment of forced inspiration. In 37 patients with COPD (GOLD
II/II/IV n Z 16/15/6, mean  SD FEV1 46.2  15.4%pred) lung function was recorded prior to
inhalation of 24 mg formoterol and 30 min later. Assessments comprised spirometry including
forced inspiration, body plethysmography, maximum inspiratory flow (InCheck, Clement
Clarke), and changes in dyspnoea via visual analogue scale (VAS). The sequence was repeated
on a second day to assess reproducibility. Bronchodilation by formoterol was detectable in all
functional indices (p < 0.05 each) except total lung capacity. FEV1 improved by (mean  SD)
11.1  10.3%, forced inspiratory volume in 1s (FIV1) by 11.6  13.5%, inspiratory peak flow (PIF)
by 10.7  16.2%, and inspiratory flow determined by the InCheck device (IF-IC) by
11.9  14.4%. Remarkably, the changes of IF-IC (p < 0.001) but not those of other measures
except FIV1 (p < 0.05) were related to those of dyspnoea. Effects on IF-IC showed reproduc-
ibility comparable to that of other indices. The results suggest that a simple, portable device
for recording forced inspiration could be useful in monitoring COPD, as a functional correlate
of acute changes in dyspnoea. (ClinicalTrial.gov number NCT00561886).
ª 2010 Elsevier Ltd. All rights reserved.eca, Wedel, Holstein, Germany.
linic, Dept. of Pulmonary Medicine, Langenbeckstr. 1, 55101 Mainz, Germany. Tel.: þ49 6131 17 6848;
ik.uni-mainz.de (C. Taube).
0 Elsevier Ltd. All rights reserved.
Forced inspiration and bronchodilation in COPD 317Introduction Study protocolThe association between clinical state and lung function in
patients with chronic obstructive pulmonary disease (COPD)
is known to be far from simple. Among other observations,
this is reflected in the weak correlation between the
functional response to bronchodilator inhalation assessed
by forced expiration and the undisputable clinical benefit
for the patient. Part of this complex relationship is based in
the multiple mechanical alterations that occur in severe
COPD and can be elucidated by the assessment of, e.g.,
forced inspiration1 and dynamic hyperinflation.2
In patients with severe COPD who are at rest, the
reduction of dyspnoea after bronchodilator inhalation has
been demonstrated to be primarily related to the
improvement of forced inspiration, such as changes in the
forced inspiratory volume in 1 s (FIV1).
1,3 Although forced
inspiration is not undemanding with regard to the patient’s
cooperation, its assessment might be more feasible in
outpatient settings and clinical routine than, for example,
the determination of dynamic hyperinflation. Moreover, in
view of the demonstrated relationship between changes in
dyspnoea and FIV1 or peak inspiratory flow (PIF),
1,3 the
assessment of forced inspiration by the patient at home
could be a particularly attractive option to obtain a func-
tional correlate of dyspnoea.
Measurements at home require a portable, robust,
affordable device, similar to conventional peak flow
meters. Such instruments are not in common use, there
are, however, devices designed for the assessment of
inspiratory flow rates in order to aid in the choice of
the inhaler most suitable for the patient. Although these
instruments, owing to their specific purpose and
construction, might yield readings that differ from those
of high-end spirometers, they could still be useful for
clinical monitoring. Recently, a detailed analysis became
available comparing one of these devices with conven-
tional lung function measures.4 We used the same device
in patients with COPD to determine whether its readings
were related to the change in dyspnoea after bronchodi-




Thirty-seven patients with COPD (GOLD II/III/IV nZ 16/15/
6)5 participated in this study (online repository Table 1). All
patients were in a stable state of their disease. Medication
was held constant throughout the study, with the exception
of short-acting and long-acting bronchodilators which were
withdrawn 8 and 24 h, respectively, before measurements.
Thirty-two patients were treated with long-acting b2-
adrenoceptor agonists, 26 patients with long-acting anti-
cholinergics, 7 patients with theophylline, and 19 patients
with inhaled corticosteroids. No patient was on oral corti-
costeroids. Fifteen patients were smokers, all others ex-
smokers. The protocol was approved by the local Ethics
Committee and patients gave their written informed
consent.The study was performed on three separate days. On day 1
a clinical history was taken and lung function measure-
ments were performed to obtain the patients’ baseline
characteristics. The other two study days had the same
sequence of assessments to determine reproducibility.
They were separated by at least 2 and maximally 14 days.
After an interval of 30 min which the patients spent at rest,
lung function measurements were performed to obtain
baseline values. Patients then inhaled 24 mg of formoterol
(2 puffs of Oxis by Turbuhaler; AstraZeneca, Wedel,
Germany); 30 min later lung function was re-assessed. The
two values before and after formoterol inhalation were
used to determine bronchodilator responses. Moreover,
patients rated their changes in dyspnoea after the 30 min
period on a visual analogue scale (VAS). It was ensured that
the patients understood the scale and the three possibili-
ties of improvement, no change, and worsening of breath-
lessness. Each subject was instructed to mark the VAS line
at any point at which he or she wished to do so. Ratings
were expressed as percents of the full VAS line length, the
range being from 100% (very much worse) to þ100% (very
much better). Patients were carefully advised to rate only
shortness of breath, and to ignore other sensations such as
cough or chest tightness.1,6,7
Assessments in the laboratory
Lung function tests consisted of body plethysmography and
spirometry including forced exspiration and forced inspi-
ration, in that order. Measurements were performed
according to the recommendations and quality standards of
the ATS/ERS8e10 or previously used standards.1 These
measurements were followed by the assessment of
maximum inspiratory flow rate using an inspiratory peak
flow meter (InCheck, Clement Clarke International Ltd,
Harlow, UK). For this manoeuvre patients slowly exhaled
until RV and then inhaled with maximal effort. The device
was used without additional resistance. At least 3 attempts
were made and the best of these was taken for analysis.
Patients were explicitly encouraged to perform maximal
manoeuvres, and values that were obviously incorrect were
discarded. The values recorded by this device are subse-
quently denoted as IF-IC values.
Data analysis
Mean values and standard deviations (SD) were taken for
data description. Baseline characteristics were compared
between the two days by the paired t-test. Bronchodilator
responses were expressed as absolute and relative changes
occurring after inhalation. These responses were also
compared between study days by the paired t-test. Addi-
tionally, analysis of variance (ANOVA) was performed, with
measuring time and day as factors, whereby differences
between responses at the 2 days would have resulted in
significant measurementeday interaction. In this ANOVA
design the factor indicating whether measurements were
performed before or after formoterol inhalation was nested
within the day factor. The validity of ANOVA assumptions
was checked by analysis of residuals.
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function indices as well as that between VAS and functional
changes was evaluated by standard analysis of covariance
(ANCOVA), using a step-down procedure for the covariates,
until only significant predictors remained. To keep the
power of the study as high as possible, data from both study
days were used; this was the basis of the ANCOVA design by
introducing an appropriate categorical variable for study
day to account for the dependence between the measure-
ments on both days. However, we also checked the results
by multilinear regression of the data of each of the two
days separately, again employing a step-down approach to
select predictors. To quantify the strength of an associa-
tion, the R as derived from ANCOVA’s R-squared was used as
an overall measure. Statistical significance was assumed if
the error of the first kind (p) was <0.05.
Results
Baseline values of all lung function measures including the
InCheck data did not statistically differ between the two
study days.
Comparison of the effect of formoterol on different
measures
There were no significant differences between the func-
tional responses to formoterol determined on the two study
days (paired t-test), for both absolute and relative changes.
This was also demonstrated by the nonsignificant ANOVA
term regarding the dayebronchodilation interaction when
including both study days. Therefore, averages of the
results of both days are presented in Table 1.
With the exception of total lung capacity (TLC), all lung
function measures assessed by spirometry and body pleth-
ysmography showed a significant bronchodilator response
to formoterol (p < 0.01 each; ANOVA). This is in line with
recent large studies, showing that spirometric changes
after inhalation of bronchodilators are frequently detected
in patients with COPD.11 The InCheck device also reflectedTable 1 Lung function measurements and changes after formo
Absolute values
Baseline Formoterol
FEV1 L 1.60  0.65 1.77  0.72
FVC L 3.27  1.17 3.58  1.23
PEF L/s 3.94  1.72 4.33  1.92
IVC L 3.41  1.19 3.70  1.26
FIV1 L 2.90  1.13 3.19  1.17
PIF L/s 4.88  1.87 5.31  1.92
IC L 2.29  0.96 2.54  1.00
ITGVa L 5.53  1.32 5.20  1.18
TLCa L 7.75  1.41 7.70  1.34
RVa L 4.28  1.19 3.84  1.14
IF-IC L/min 196.9  84.7 216.8  86.8
The table shows mean values (SD) of the data averaged over the two
ANOVA comprising both study days. There were no significant diffe
indicated by the factor for day and the interaction term.
a n Z 31 due to lack of technically acceptable values in the measubronchodilation. This was true irrespectively of the fact,
whether each of the two study days was analysed sepa-
rately (paired t-test, p < 0.0001, both comparisons) or
whether both study days were analysed together (ANOVA,
p < 0.0001; Table 1).
Formoterol also improved dyspnoea ratings. VAS scale
changes did not significantly differ between the two study
days (paired t-test). On average, the mean (SD) change
was 34.7  26.9 mm and in the subgroup of stage III/IV
patients 39.2  26.5 mm. All values were greater than zero
according to their 99%-confidence intervals, when evalu-
ated either separately for the two days or as an average
(confidence interval according to t-distribution).
Relationship of IF-IC to other lung function
measures
Most of the functional measures were strongly correlated
with each other which led to difficulties in the multivariate
step-down approach that was chosen to identify indepen-
dent predictors of IF-IC. In particular, analyses could only
be reasonably performed with either PIF or FIV1 as cova-
riate, not with both of them.
ANCOVA of the data obtained at both study days
comprising absolute values of IF-IC as dependent variable
and spirometric measures as covariates showed that IF-IC
was consistently related only to PIF and PEF for both
baseline and post-bronchodilator measurements (p < 0.01,
both comparisons), whereby the normalized regression
coefficients of PIF and PEF were similar. Analogous results
were obtained by multilinear regression, if analysis was
performed for each of the two days separately. When
expressed in comparable units with regard to volume and
time, the absolute readings of IF-IC were significantly lower
than those of PIF assessed by a pneumotachograph (ANOVA,
p < 0.001).
A similar analysis strategy was applied to the relative
changes of IF-IC after formoterol inhalation. These changes
turned out to be significantly associated with those of FIV1
only (p < 0.001 ANCOVA, Fig. 1). The correlation betweenterol inhalation.
Changes
p-value* absolute percent
<0.0001 0.16  0.16 11.1  10.3
<0.0001 0.31  0.30 10.7  11.3
<0.001 0.39  0.87 15.9  57.4
<0.0001 0.30  0.27 9.9  10.4
<0.0001 0.29  0.30 11.6  13.5
<0.0001 0.43  0.70 10.7  16.2
<0.0001 0.25  0.38 15.1  25.2
0.009 0.33  0.91 4.2  18.0
0.676 0.05  0.88 0.1  11.1
<0.001 0.43  0.95 8.4  20.4
<0.0001 19.9  24.9 11.9  14.4
study days. *p-values as derived from repeated-measures nested























Figure 1 Plot of the relative changes of IF-IC after for-
moterol inhalation versus those of FIV1. This was the only
statistically significant association of IF-IC with functional
measures remaining in multivariate analysis (p < 0.001). Data
from the first study day are shown as rectangles, those from
the second day as circles. Closed symbols indicate patients of
GOLD stages III/IV, open symbols stage II.
Forced inspiration and bronchodilation in COPD 319the mean relative changes of IF-IC and FIV1 as derived by
ANCOVA was RZ 0.41. In contrast, the absolute changes of
IF-IC were related to those of FIV1 (p < 0.05) as well as PIF
(p < 0.001, online repository Fig. 2).
Relationship between changes in lung function and
dyspnoea
Firstly, the post-bronchodilator changes as percent of
baseline of several functional measures were compared
with dyspnoea, using multivariate ANCOVA of the data












Figure 2 Relationship between the percent changes of IF-IC
and the change in dyspnoea as quantified by the VAS scale.
Responses observed on the first study day are given as rect-
angles, responses from the second day as circles. Patients of
GOLD stages III/IV are indicated by closed symbols, patients of
stage II by open symbols.FIV1 (p < 0.05) (online repository Fig. 3) were signifi-
cantly related to the changes of VAS. Corresponding
correlation coefficients were R Z 0.48 and 0.24,
respectively. When analysing different severities of
COPD, the relationship between VAS and IF-IC was
statistically significant in patients of stage II (p < 0.05)
and III/IV (p < 0.001), while that between VAS and FIV1
was significant only in stage III/IV (p < 0.05). Similar
results were obtained when using the absolute instead of
percent changes of the functional measures or analysing
both study days separately.Discussion
The results of the present study demonstrate that a simple
device for measuring maximum inspiratory flow rate yiel-
ded readings that correlated with the change in dyspnoea
after bronchodilator inhalation in patients with COPD. This
correlation was better than that with any other functional
measure across a panel of spirometric and body plethys-
mographic indices. The finding is in accordance with
previous reports demonstrating that primarily indices of
forced inspiration, such as FIV1 and PIF, but not those of
forced expiration, such as FEV1 and PEF, were related to
the reduction in dyspnoea upon bronchodilation in patients
with moderate to severe COPD. This suggests that the
portable device might be useful in the assessment of short-
time changes in dyspnoea and acute treatment effects in
these patients.
Dyspnoea experienced by individuals who complain of
unpleasant or uncomfortable respiratory sensations12 is the
key symptom in COPD. The sensation of dyspnoea is expe-
rienced differently among individuals with COPD and may
be based on diverse factors, such as muscle fatigue,
perceptional thresholds, or trapped air volumes.13 Changes
in dyspnoea following bronchodilator inhalation have been
associated especially with changes in forced inspiratory
volumes at rest1,3,6,14 and changes in inspiratory capacity
during exercise.2,15,16 In line with the present ANCOVA
results, a tentative factor analysis (not shown) of the data
confirmed our earlier findings on the association between
FIV1 and dyspnoea,
1 as well as the observation that the
association between FIV1 and VAS was most pronounced in
severe disease.
As the spirometric measurements are commonly per-
formed using sensitive, rather expensive instruments or, in
case of inspiratory capacity, within special experimental
set-ups, the question arises whether similar assessments
would be possible using simpler devices. The type of
portable inspiratory peak flow meter evaluated by us had
been used previously to help with the choice between
different dry powder inhalers in patients with COPD.4,17e19
In these studies different resistances were added to mimic
the internal resistance of the different inhalers. In the
present study we used the instrument without additional
resistance in order to obtain an unimpeded, or at least not
deliberately impeded, maximum flow rate. Values were
considerably lower than those determined by a high-end
spirometer, indicating that the mechanical set-up of the
instrument per se involved a non-negligible internal resis-
tance and/or inertance.
320 C. Taube et al.At first sight this might appear as a disadvantage, but the
result that the correlation of IF-IC with dyspnoea was even
higher than that of FIV1 a forteriori suggested that the
limitations of the instrument had even raised its potential
value. Previous studies in patients with cystic fibrosis or
COPD have shown that peak inspiratory flow measured with
a pneumotachograph did not correlate with disease
severity, as indicated by FEV1%predicted, but only with
maximal inspiratory pressure.20 Noteworthy enough, in
a recent study in elderly patients with COPD, IF-IC corre-
lated with spirometric PIF, forced vital capacity (FVC) and
maximum inspiratory pressure.4 Since we were primarily
interested in the association with changes in dyspnoea as
a basis for possible clinical applications, we did not focus on
physiological measures potentially explaining IF-IC read-
ings. In particular we did not expect short-term functional
changes in inspiratory pressure and thus omitted this type
of measurement from our study.
The difference between the functional relationships
found in the previous4 and the present study was most
likely due to the fact that patients of different severity
were included. The pattern of relationships of IF-IC,
particular that with VAS, turned out to be predominantly
due to the patients of GOLD stage III/IV (see Fig. 2). When
analysing this stage separately, the association of the
changes of IF-IC with VAS remained highly significant,
whereas in stage II it became weaker, although it was still
present (p Z 0.019). Moreover, the association between
the percent changes of IF-IC and FIV1 as observed in the
total group was maintained in stage III/IV patients; for
absolute changes, the association with PIF remained in
stages II and III/IV, while that with FIV1 was significant only
in stage III/IV. Especially the observations regarding dysp-
noea indicated that the present data were consistent with
our previous results1 in showing the strongest association
between changes of dyspnoea and inspiratory lung function
in patients with severe disease. Using other, more
demanding techniques such as the determination of
dynamic hyperinflation during exercise challenge, also
patients with mild COPD can show an association between
exertional dyspnoea and abnormal dynamic ventilatory
mechanics.21
The potential clinical applicability of the IF-IC
measurements depends on their reproducibility. Spiro-
metrically determined changes in FIV1 following broncho-
dilator inhalation show only slightly higher variability as
FEV1.
3 In the present study variability of IF-IC also appeared
to be similar to that of spirometric measures and accept-
able according to the comparative Bland & Altman plots
(online repository Fig. 1). In the common view, forced
inspiration seems to demand a higher degree of coopera-
tion than forced expiration but this might be due to a lack
of experience. Its usefulness is also limited in patients with
a low degree of airway obstruction, since these will
complete their inspiration within 1 s, leaving no room for
the assessment of improvements. On the other hand,
severely ill patients often complain about forced expiratory
manoeuvres which cause dyspnoea, and it might well be
that forced inspiration turns out to be easier and more
acceptable if patients become acquainted to it.
In conclusion, the data of this study indicated that the
portable inspiratory flow meter used in this study wascapable of reproducibly detecting the functional response
to bronchodilator inhalation in patients with moderate to
severe COPD. Most importantly, the readings of this
instrument were better correlated with the concomitant
reduction of dyspnoea than lung function parameters that
are conventionally used to describe the functional
improvement in COPD. This suggests that the device could
provide an objective correlate of changes of dyspnoea and
in particular short-term therapeutic responses in COPD,
better than conventional measurements of forced expira-
tion. It remains to be assessed whether home monitoring by
this instrument is feasible and provides useful clinical
information on the state and course of the disease in COPD.Conflict of interest
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